NCT02220296 - A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

HealthyDiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

Insulin 338

Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).

DRUG

placebo

Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).

DRUG

Insulin 338

Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).

DRUG

insulin glargine

Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss